Plasma fibrinogen: Now also an antidepressant response marker?

Translational Psychiatry

Volumn 4, Issue , 2014, Pages

  Martins De Souza, D ^a,b,c   Maccarrone, G ^a   Ising, M ^a   Kloiber, S ^a   Lucae, S ^a   Holsboer, F ^a   Turck, C W ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Antidepressant; Biomarkers; Drug response; Fibrinogen; Proteomics

Indexed keywords

ANTIDEPRESSANT AGENT; FIBRINOGEN; PROTEOME; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; MALE; MASS SPECTROMETRY; MIDDLE AGED; TREATMENT RESPONSE; VERY ELDERLY; WESTERN BLOTTING; YOUNG ADULT; MAJOR DEPRESSION; PROTEIN BLOOD LEVEL; BLOOD; DEPRESSIVE DISORDER, MAJOR; TREATMENT OUTCOME;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER, MAJOR; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; PROTEOME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893354179     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2013.129     Document Type: Article

References (24)

1. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 2101-2107. (Pubitemid 30482715)
2. Rosenzweig-Lipson S, Beyer CE, Hughes ZA, Khawaja X, Rajarao SJ, Malberg JE et al. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 2007; 113: 134-153. (Pubitemid 46017069)
3. Nrugham L, Holen A, Sund AM. Suicide attempters and repeaters: depression and coping: A prospective study of early adolescents followed up as young adults. J Nerv Ment Dis 2012; 200: 197-203.
4. Martins-de-Souza D, Harris LW, Guest PC, Turck CW, Bahn S. The role of proteomics in depression research. Eur Arch Psy Clin Neurosci 2010; 260: 499-506.
5. Wium-Andersen MK, Orsted DD, Nordestgaard BG. Association between elevated plasma fibrinogen and psychological distress, and depression in 73 367 individuals from the general population. Mol Psychiatry 2012; 18: 854-855.
6. Hennings JM, Owashi T, Binder EB, Horstmann S, Menke A, Kloiber S et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients -findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 2009; 43: 215-229.
7. Wium-Andersen MK, Orsted DD, Nordestgaard BG. Elevated plasma fibrinogen, psychological distress, antidepressant use, and hospitalization with depression: Two large population-based studies. Psychoneuroendocrinology 2012; 38: 638-647.
8. Panagiotakos DB, Pitsavos C, Chrysohoou C, Tsetsekou E, Papageorgiou C, Christodoulou G et al. Inflammation, coagulation, and depressive symptomatology in cardiovascular disease-free people; the ATTICA study. Eur Heart J 2004; 25: 492-499. (Pubitemid 38524274)
9. Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W et al. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res 1997; 66: 1-11. (Pubitemid 27111375)
10. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK et al. A metaanalysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-457.
11. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: A meta-analysis. Psychosom Med 2009; 71: 171-186.
12. Krishnadas R, Cavanagh J. Depression: An inflammatory illness? J Neurol Neurosurg Psychiatry 2012; 83: 495-502.
13. Muller N, Myint AM, Schwarz MJ. Inflammatory biomarkers and depression. Neurotox Res 2011; 19: 308-318.
14. Dantzer R, O'Connor JC, Lawson MA, Kelley KW. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011; 36: 426-436.
15. Duivis HE, de Jonge P, Penninx BW, Na BY, Cohen BE, Whooley MA. Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: prospective findings from the heart and soul study. Am J Psychiatry 2011; 168: 913-920.
16. Baune BT, Neuhauser H, Ellert U, Berger K. The role of the inflammatory markers ferritin, transferrin and fibrinogen in the relationship between major depression and cardiovascular disorders -The German Health Interview and Examination Survey. Acta Psychiatr Scand 2010; 121: 135-142.
17. Vasse M, Paysant J, Soria J, Collet JP, Vannier JP, Soria C. Regulation of fibrinogen biosynthesis by cytokines, consequences on the vascular risk. Haemostasis 1996; 26(Suppl 4): 331-339. (Pubitemid 26417452)
18. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65: 732-741.
19. Catena-Dell'Osso M, Rotella F, Dell'Osso A, Fagiolini A, Marazziti D. Inflammation, serotonin and major depression. Curr Drug Targets 2013; 14: 571-577.
20. Fish RJ, Neerman-Arbez M. Fibrinogen gene regulation. Thromb Haemost 2012; 108: 419-426.
21. Yusuf S, Lessem J, Jha P, Lonn E. Primary and secondary prevention of myocardial infarction and strokes: An update of randomly allocated, controlled trials. J Hypertens Suppl 1993; 11: S61-S73. (Pubitemid 23226741)
22. Meade TW. Haemostatic function and arterial disease. Br Med Bull 1994; 50: 755-775. (Pubitemid 24360965)
23. He S, Blomback M, Yoo G, Sinha R, Henschen-Edman AH. Modified clotting properties of fibrinogen in the presence of acetylsalicylic acid in a purified system. Ann N Y Acad Sci 2001; 936: 531-535. (Pubitemid 32613938)
24. Caspary EA. Studies on the acetylation of human fibrinogen. Biochem J 1956; 62: 507-512.